Global RWE Oncology Market Research Report 2022

Company Logo

Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) — The “RWE Oncology Market by Component, Application, End User – Global Forecast to 2029” report has been added to’s offering.

The RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022-2029 to reach $1.65 billion by 2029.

After a comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides insights into key industry drivers, restraints, challenges, and opportunities of the RWE oncology solutions market.

The growth of this market is driven by factors such as the rising prevalence of cancer, the rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants in this market.

Based on component, in 2022, the real-world datasets segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment data is attributed to the growing amount of medical generated in hospitals, increasing on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers .

Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.

Based on end user, in 2022, the pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment studies is attributed to the importance of RWE in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

In 2022, North America is expected to command the largest share of the global RWE oncology solutions market, followed by Europe and Asia-Pacific.

Market Insights


  • Growing Burden of Cancer

  • Rising Focus Towards Personalized Healthcare

  • Delays in Drug Development and the Subsequent Increase in Development Costs

  • Shift Towards Value-based Care

  • Rapidly Growing Big Data in Healthcare



  • Emerging Economies

  • Rising Focus on End-to-end RWE Services

  • Rising Adoption of Wearable Devices, Mobile Apps, and Artificial Intelligence in RWE


Key Market Trends

  • Growing Adoption of RWE in Drug Development and Commercialization

  • Rising Number of Consolidations

  • Improved Patient Outcomes and value Creation from Real-world Evidence

Company Profiles

  • IQVIA Holdings Inc.

  • ICON plc

  • PPD Inc.



  • Medpace Holdings Inc.

  • Symphony Innovation LLC

  • Clinigen Group plc

  • Cognizant Technology Solutions Corporation

  • Oracle Corporation

  • PAREXEL International Corporation

  • PerkinElmer Inc.

  • SAS Institute Inc.

  • UnitedHealth Group Incorporated

  • Flatiron Health

Scope of the Report:

RWE Oncology Solutions Market, by Component

RWE Oncology Solutions Market, by Application

  • Drug Development & Approvals

  • Market Access & Reimbursement/Coverage Decisions

  • Post-market Surveillance

  • Medical Device Development & Approvals

  • Other Applications

RWE Oncology Solutions Market, by End User

RWE Oncology Solutions Market, by Geography

  • North America

  • US

  • Canada

  • Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Europe (RoE)

  • Asia-Pacific (APAC)

  • Japan

  • China

  • India

  • South Korea

  • Taiwan

  • Singapore

  • Rest of APAC (RoAPAC)

  • Latin America

  • Middle East & Africa

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Comment

Your email address will not be published.